The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty
- 199 Downloads
Postoperative anemia is a common complication after total hip arthroplasty (THA). However, the effect of edoxaban on postoperative anemia after THA remains unclear. Here, we retrospectively evaluated the clinical assessment of postoperative anemia and the associated changes of coagulation parameters in patients undergoing thromboprophylaxis with edoxaban compared with fondaparinux as a conventional anticoagulant thromboprophylactic agent after THA.
One hundred and forty-nine patients who underwent THA from July 2010 to June 2012 were divided into two groups, according to whether they were operated on before or after the approval of edoxaban: the fondaparinux group (Group F: 86 patients) and the edoxaban group (Group E: 63 patients). The frequency of postoperative anemia and blood coagulation values were investigated.
Postoperative anemia developed more frequently in Group E than in Group F after surgery. However, the degree of postoperative anemia showed no significant difference between the groups. Meanwhile, prothrombin time (PT), prothrombin time-international normalized ratio (PT-INR), and activated partial thromboplastin time were markedly higher in patients with edoxaban-associated postoperative anemia, which showed an increased potential to predict the occurrence of postoperative anemia. Additionally, both PT and PT-INR in Group E were also correlated with the volume of estimated blood loss.
The frequency of postoperative anemia was increased in patients treated with edoxaban, compared to fondaparinux, after THA. Edoxaban thromboprophylaxis might, therefore, require more careful monitoring to prevent postoperative anemia. Additionally, particular prolongation of PT and PT-INR induced by edoxaban treatment might predict postoperative anemia.
KeywordsEdoxaban Total hip arthroplasty Postoperative anemia Prothrombin time
We thank Yusuke Ookura, Akimasa Yoshida, Kazuma Koga, Yuko Kuwada, Anna Ueno, Satomi Tani, Shunki Ishihara for helpful discussion and assistance with all our data analyses. Repeatedly, all of them helped with the data extraction from their respective database and ensured the high quality of the data by numerous quality checks.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Liu X, Zhang X, Chen Y, Wang Q, Jiang Y, Zeng B (2011) Hidden blood loss after total hip arthroplasty. J Arthroplasty 26(1100–1105):e1Google Scholar
- 5.Daiichi Sankyo Limited. Daiichi Sankyo launches LIXIANA®tablets (edoxaban), a direct oral factor Xa inhibitor, in Japan for the prevention of venous thromboembolism after major orthopedic surgery: first direct oral factor Xa inhibitor available to Japanese patients. http://www.daiichisankyo.co.jp/news/detail/005457.html. Accessed 10 Jan 2018
- 12.Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Thrombolysis 8:202–204CrossRefGoogle Scholar
- 14.European Medicines Agency/Committee for Medicinal Products for Human Use (CHMP) (2013) Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143764.pdf. Accessed 7 Jan 2018